Morgan Stanley Regulus Therapeutics Inc. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 77,621 shares of RGLS stock, worth $632,611. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77,621
Previous 139,791
44.47%
Holding current value
$632,611
Previous $220,000
38.64%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RGLS
# of Institutions
79Shares Held
53.7MCall Options Held
104KPut Options Held
4.1K-
Federated Hermes, Inc. Pittsburgh, PA15.8MShares$129 Million0.06% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$52.7 Million1.07% of portfolio
-
Octagon Capital Advisors LP New York, NY4.64MShares$37.8 Million2.7% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$32.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.95MShares$32.2 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $119M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...